Microfloppies Systems Have Potential to Help Millions of Diabetics

microfloppies while “nanotechnology” has been a common buzzword among investors. Researchers, “nanotechnology” has graduate, from university research laboratories into commercial reality. MEMS (Small Electromagnetically System) technology has been around since the late 1970s . Saw a massive increase in popularity in the 1990s in the telecommunications industry. Because it could be use to make optical fiber switches at a microfloppies microscopic scale.

Microfloppies Systems Have Potential to Help Millions of Diabetics

Microfloppies Systems Have Potential to Help Millions of Diabetics

microfloppies the industry sees benefits

Recently, the pharmaceutical medical equipment industry,  has realize the benefits of microelectronic, microfloppies systems. Which has led to the development of a whole new industry, of  microfloppies drug delivery systems. Although many drugs are use in microfloppies systems, insulin is what attracts both consumers and the industry the most, to diabetics. With the rise in insulin-dependent diabetes.

There is a large market for painless implantable robotic insulin devices. That provide accurate doses base on patient needs that are automatically detect. As always, these devices have to be inexpensive. So which means that the MEMs manufacturing process must be able to mass-produce. Something that has been a challenge until recently.

Composition of microfloppies systems

Microfloppies drug delivery systems have three main components. Needle set, pump, valve system, and chemical sensors. A needle group usually consists of hundreds of needles drill with, a microscopic, silicon wafer with holes for the drug to pass through. Since these needles are so small. As per they are painless and yet deliver a large amount of the substance right away.

Integrated solutions are showing promise

Market leaders in microfloppies insulin pumps such as ISSYS, Exigent. Biotech and Biophys focus on integrate solutions that can be mass-produce. They understand that the key to success is inexpensively providing a complete system that can be implant in an outpatient setting, monitor the sensors in the sensor system, and refill with insulin by the patient.

The market for microfloppies insulin pumps is expect to reach 2 billion DKK. The dollar in 2010 with significant continuous growth over the next ten years.

Breast cancer, blood cells, and pacemakers

The biochemical signals that control, breast cancer cell migration are poorly understood. But new microfloppies devices specifically design to track. How breast cancer cells move in response to chemical signals are in development. This will allow doctors to reduce the amount of toxicity drugs.

So that are given to the patient and allow. These drugs to target only cancer cells, rather. So than the cells they are in contact with. For women with breast cancer. per so  this can mean an end to hair loss, debilitating fatigue. Other harmful side effects associate with chemotherapy.

The possibilities seem endless

For the medical equipment industry, so this is a wake-up call to search for MEM and MICS solutions to the major problems we face in the United States. as per With the increasing epidemics of obesity, diabetes, heart disease and cancer,

countless opportunities

there are countless opportunities for companies large. Small to develop sensor-base diagnostic. Treatment devices that help patients live longer. healthier lives with less invasive procedures.



You May Also Like


Leave a Comment

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>